Recent research points to IL‐17-mediated pathways playing a role in the pathogenesis of PRS, as well as in scleroderma, suggesting that disturbed immune reactions may contribute to tissue atrophy in both conditions [5-7]. This evidence concerns the gene IL17A and scleroderma.